KRAS and EGFR mutations are usually present in the founder clones of lung adenocarcinoma, while TP53 mutations are frequently acquired during advanced stages of tumor development, thus suggesting a role during tumor progression [324]. This evidence concerns the gene TP53 and neoplasm.